CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Portfolio Pulse from
CalciMedica Inc. reported its Q3 2024 financial results, highlighting positive data from its CARPO Phase 2b trial for Auxora™ in acute pancreatitis. The company plans to start a Phase 3 program in 2025. Enrollment continues for trials in acute kidney injury and asparaginase-induced pancreatic toxicity, with data expected in 2025. Following a public offering, CalciMedica's cash position is expected to support operations until mid-2026.
November 13, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CalciMedica reported positive Q3 2024 results, with promising data from its CARPO Phase 2b trial for Auxora™ in acute pancreatitis. The company plans to initiate a Phase 3 program in 2025, and its cash position is strong following a public offering.
The positive trial data and the announcement of a Phase 3 program are likely to boost investor confidence in CalciMedica. The company's strong cash position following a public offering further supports its operational stability, potentially leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100